June 23, 2009 – Abbott said today it received CE mark (Conformite Europeenne) for its next-generation Xience PRIME Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
The company plans to launch Xience PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
